Bliss GVS Pharma Ltd (BLISSGVS) — share price & stock analysis

Market cap

₹5,553 Cr

P/E

42.5×

ROE

11.6%

vs own 10-yr valuation

highest ever

Book value / share

₹113

EPS (TTM)

₹12.4

10-yr median P/E

15.7×

Revenue (FY26)

₹927 Cr

Profit after tax (FY26)

₹135 Cr

Weinstein stage

Stage 2 (53 weeks)

Data as of

1 July 2026

5 of the 6 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 17% — decent; effectively no debt; margins near the bottom of their band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.

Most of this rally is re-rating, not earnings

Since Mar 2016, the stock is up 295% while earnings per share grew 54%. The difference is re-rating — investors paying more for the same rupee of profit.pricettm_eps

That works until it doesn’t: from here, earnings have to do the lifting, because the multiple has already done its part.

Today’s P/E of 42.5× is about the most expensive this stock has ever traded against its own 10-year history.pe_ratio

Price is the weekly close (₹). EPS is trailing-twelve-month profit per share, anchored on Screener's own snapshots; between snapshots it is filled from price ÷ P/E (an exact identity), and any fill straying more than 18% from the neighbouring snapshots is dropped rather than shown. The lower panel is the P/E — what the market pays per rupee of profit; the dotted line is its long-run median (15.7×).

Stage 2: the trend is up, and has been for 53 weeks

Price trends have a life cycle: they base (1), advance (2), top out (3) and decline (4). This chart is in Stage 2: advancing — 53 weeks so far, confirmed.stage

The price sits above its rising 200-day average (₹258 today) and its strength against the index is still improving — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

Beating NIFTY 500 for 34 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Profits are at an all-time high

Over 12 years, sales went from ₹345 Cr to ₹927 Cr (about 9% a year), and profit from ₹41.0 Cr to ₹135 Cr.revenuenet_profit

Margins gave up 2.9 points along the way — growth bought at a price.operating_profit

Sales jumped 30% last quarter — the 4th straight quarter of growth

Mar 26 sales were ₹257 Cr, up 30% on the same quarter last year.revenue

That makes 4 quarters of growth in a row — this is a trend, not a blip.revenue

Margins are widening — 11% → 17% in a year

Of every ₹100 of sales, the company keeps ₹17.3 as operating profit (a year ago it kept ₹10.7).opm_pct

Zoom out and this is the page's quiet hero: annual operating margin bottomed at 15.6% in FY23 and has been rebuilt to 17.7% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit

The gross margin moved the same way (50% → 56%), so this is about input costs and pricing power — the raw-material equation improved.gpm_pctopm_pct

Profit exploded 118% — mostly from keeping more of each sale

Mar 26 profit after tax was ₹37.0 Cr, up 118% year on year.net_profit

The profits are real — they turn into cash

Over the last 5 profitable years, the business reported ₹407 Cr of profit and collected ₹517 Cr of operating cash — about 127% conversion.operating_cash_flownet_profit

One asterisk on that strength: suppliers are being paid 26 days later than a year ago (63 → 89 days). Cash flattered by stretching payables is real cash — but it is borrowed timing, not extra earning power.payable_days

The cash cycle is stable

One rupee now takes about 244 days to go out the door as materials and come back as collected cash.cash_conversion_cycle

The biggest mover: suppliers being paid later (63 → 89 days).payable_days

The asset base keeps compounding — this company builds

The productive asset base has gone from ₹213 Cr (FY14) to ₹459 Cr, with another ₹6.0 Cr of capacity under construction right now.fixed_assetscwip

The build is self-funded: the last 3 years' investing outflow (₹196 Cr) fits inside the operating cash the business generated (₹348 Cr).investing_cash_flowoperating_cash_flow

Almost no debt — this company cannot be killed by a bad year

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹2 — total borrowings have shrunk from ₹173 Cr to ₹22.0 Cr over the window.borrowings

Every ₹100 kept in the business earns ₹17 — decent, not special

Return on capital employed is 17.0% (a year ago: 12.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

Rising returns on capital while growing is the rarest combination in investing — it means the new projects earn more than the old ones.roce_pct

Institutions have been lightening up

Promoters hold 35.4%, essentially unchanged. Foreign funds own 10.4%, domestic funds 5.0%.promoters_pctfiis_pctdiis_pct

Meanwhile foreign funds have been the sellers — from 16.5% to 10.4% over the window. Someone on the other side of the table disagrees; both sides count.fiis_pct

A good business — the question is the price

The numbers are genuinely mixed, and the price already assumes the good news continues.

Best thing in the data: free cash flow rising (₹31.0 Cr → ₹101 Cr).operating_cash_flow

Biggest worry: domestic-fund holding falling (6.5% → 5.0%).diis_pct

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

Straight answers from the data